Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molidustat plus ivosidenib in relapsed or refractory IDH1-mutated AML or MDS/AML
2024-514051-15-00Phase 2Authorised
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of molidustat and ivosidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Medizinische Hochschule Hannover. Primary endpoints: Frequency of dose-limiting toxicities and Complete remission rate. Planned start Jul 2023; status: authorised.
02
Drugs
molidustativosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-514051-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514051-15-00.